Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Antibody-Drug Conjugate SC16LD6.5

Known as: Anti-SC16 ADC SC16LD6.5, SC16LD6.5 
An antibody-drug conjugate (ADC) containing an antibody directed against the scr-like kinase Fyn3 (SC-16), conjugated to the cytotoxic agent D6.5… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
DLL3 is overexpressed in neuroendocrine prostate cancer and is a potential therapeutic target. Lessons from one tumor help with… Expand
Is this relevant?
2017
2017
The Notch ligand DLL3 has emerged as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade… Expand
Is this relevant?
2017
2017
Expression of DLL3 was examined in additional tumor types, as it was found to be highly expressed in tumor-initiating cells (TIC… Expand
Is this relevant?
2016
2016
LBA8505Background: SCLC remains among the most deadly of malignancies. Rovalpituzumab tesirine is a first-in-class ADC comprised… Expand
Is this relevant?
2016
2016
ABSTRACT Delta-like protein 3 (DLL3) is a novel and tractable tumor-initiating cell-associated target for the antibody-drug… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers… Expand
Is this relevant?
2003
2003
An in situ study of the kinetics of relaxation of the gamma-gamma' lattice mismatch in the single-crystal Ni-base superalloy SC16… Expand
Is this relevant?
2003
2003
Thermodynamic equilibrium and Gulliver – Scheil as well as diffusion calculations using the DICTRA program have been made to… Expand
Is this relevant?
2001
2001
 
Is this relevant?
1995
1995
A first-principles pseudopotential study of the phase stability of the III-V semiconductors GaAs and AlAs is reported. For both… Expand
Is this relevant?